Israel headquartered Scopio Labs, developer of Full-Field Cell Morphology imaging and analysis platform, has announced the unveiling of its groundbreaking Complete Blood Morphology (CBM®) analyser.
CBM will bring unprecedented scale, efficiency and standardisation to hematology through autonomous morphology analysis and reporting, one of the last remaining manual processes in diagnostics.
To expedite the go-to-market of CBM®, Viola Growth has joined as a new investor with a $10 million extension to Scopio's Series D funding, bringing the total to $52 million.
CBM® is built on top of Scopio's proprietary Full-Field technology, leveraging advanced computational imaging and AI-powered analysis to transform current PBS review workflow into an autonomous, standardised, and clinically relevant process, analysing 10x more cells than the current standard of care in blood cell morphology. Hematology labs currently utilising Scopio's Full-Field PBS platform are already alleviating some of the pain points, while laying the essential groundwork for rapid CBM® adoption, effectively future-proofing their operations.
Scopio Labs currently has CE-marked and US FDA-cleared digital imaging applications in the market, including applications for peripheral blood smear and bone marrow aspirate analysis.
